Correlation between Expression of Estrogen Receptor and Progesterone Receptor and Clinicopathologic Factors in Patients with Primary Breast Cancer_West China Medical Journal

Authors：

 GUOShao-feng ,  WANGXiao-ming , ZHAOJin-hua , YANHao , WUXue-mei , WENLi-jun , DAIWu-zhuang , HUANGYuan

Department of Pathology, People's Hospital of Meishan City, Meishan, Sichuan 620000, P. R. China;

Corresponding?author：

WANGXiao-ming, Email: 2318675158@qq.com

Keywords：

Estrogen receptor; Progesterone receptor; Breast cancer; Clinical pathology

DOI：

10.7507/1002-0179.20140013

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To explore the correlation of clinicopathologic factors with the expression of estrogen receptor (ER) and progesterone receptor (PR) in patients with primary breast cancer. Methods The data of 105 patients with primary breast cancer were collected from September 2011 to September 2012. The expression of ER, PR and C-erbB-2 in breast cancer tissues was detected by immunohistochemistry. The correlation between the expression of ER, PR and C-erbB-2 and the clinicopathologic factors was evaluated. Results The positive rates of expression of ER, PR and C-erbB-2 in breast cancer tissues reached 58.1%, 49.5% and 59.0%, respectively. The expression of ER had a positive correlation with the expression of PR. The concordance expression of ER and PR had a negative correlation with the expression of C-erbB-2. The positive rate of expression of ER had a correlation with the lymph node metastasis and histological grading, while it was not correlated with patients' age, the age of menarche, tumor size, tumor position, clinical stages, pathological type, or pathologic morphology of tissue adjacent to cancer (P>0.05). The positive rate of expression of PR and the different positive strength rate of expression of ER were not correlated with clinical and pathological factors (P>0.05). The positive rate of expression of C-erbB-2 in the group with lymph node metastasis was higher than that in non-lymph node metastasis group (P<0.05). Conclusion The expression of ER and PR plays an important role in the occurrence and development of the breast cancer. Joint detection of ER and PR is very important for the evaluation of endocrine therapy effect and prognosis.

Citation： GUOShao-feng, WANGXiao-ming, ZHAOJin-hua, YANHao, WUXue-mei, WENLi-jun, DAIWu-zhuang, HUANGYuan. Correlation between Expression of Estrogen Receptor and Progesterone Receptor and Clinicopathologic Factors in Patients with Primary Breast Cancer. West China Medical Journal, 2014, 29(1): 47-50. doi: 10.7507/1002-0179.20140013 Copy

1.	Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1):243-250.
2.	尹洪芳, 王韞宏, 秦小琪, 等. 新輔助化療對乳腺癌的組織學分級和生物學指標表達的影響[J]. 中華腫瘤雜志, 2011, 31(11):858-862.
3.	Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2):200-214.
4.	王艷, 霍翔, 沈洪兵. 雌激素受體和孕激素受體與乳腺癌關系的研究進展[J]. 中國腫瘤, 2007, 16(12):987-990.
5.	Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer:a validation study[J]. Mod Pathol, 2004, 17(12):1545-1554.
6.	Stendahl M, Rydén L, Nordenskj?ld B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients[J]. Clin Cancer Res, 2006, 12(15):4614-4618.
7.	鄧窈窕, 張麗, 蔣明, 等. 乳腺癌患者激素受體、人表皮生長因子受體2表達與免疫組織化學分子亞型分析[J]. 華西醫學, 2012, 27(4):491-494.
8.	劉曉光, 徐光煒. C-erbB-2、P53及nm23基因及產物在乳腺癌預后中的意義[J]. 中國腫瘤臨床, 1994, 21(5):391-395.
9.	韓晶, 王培軍, 湯如勇, 等. HER-2基因在乳腺癌中的表達及其與雌激素受體亞型的關系[J]. 第二軍醫大學學報, 2006, 27(11):1268-1269.
10.	Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index[J]. Breast Cancer Res, 2009, 11(2):R18.
11.	Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma[J]. Breast J, 2005, 11(4):278-280.
12.	李文華, 孫奇, 覃希, 等. ER、PR、C-erbB-2、HMFG在乳腺癌組織中的表達及臨床意義[J]. 山東醫藥, 2011, 51(47):54-56.
13.	郭麗英, 郭晨明, 馬方婧, 等. 乳腺癌雌激素受體表達和臨床病理因素的關系[J]. 新疆醫科大學學報, 2009, 32(1):48-50.
14.	胡應光. 乳腺癌ER、PR、P53、C-erbB-2表達的臨床意義[J]. 中國基層醫藥, 2007, 14(6):941-942.
15.	姚衛康, 包建英, 吳德明, 等. C-erbB-2、ER、PR在乳腺癌中的表達及其臨床意義[J]. 蘇州大學學報·醫學版, 2007, 27(4):569-571.
16.	闞秀, 沈丹華, 史斌, 等. 關于乳腺普通性增生、不典型增生和原位癌相互關系及鑒別診斷的探討[J]. 中華病理學雜志, 2004, 33(4):14-17.
17.	李金鋒, 鄭德清. 乳腺浸潤癌癌前病變的研究現狀[J]. 國外醫學·腫瘤學分冊, 2002, 29(3):213-216.

1. Yang L, Parkin DM, Ferlay J, et al. Estimates of cancer incidence in China for 2000 and projections for 2005[J]. Cancer Epidemiol Biomarkers Prev, 2005, 14(1):243-250.
2. 尹洪芳, 王韞宏, 秦小琪, 等. 新輔助化療對乳腺癌的組織學分級和生物學指標表達的影響[J]. 中華腫瘤雜志, 2011, 31(11):858-862.
3. Kurebayashi J. Current clinical trials of endocrine therapy for breast cancer[J]. Breast Cancer, 2007, 14(2):200-214.
4. 王艷, 霍翔, 沈洪兵. 雌激素受體和孕激素受體與乳腺癌關系的研究進展[J]. 中國腫瘤, 2007, 16(12):987-990.
5. Mohsin SK, Weiss H, Havighurst T, et al. Progesterone receptor by immunohistochemistry and clinical outcome in breast cancer:a validation study[J]. Mod Pathol, 2004, 17(12):1545-1554.
6. Stendahl M, Rydén L, Nordenskj?ld B, et al. High progesterone receptor expression correlates to the effect of adjuvant tamoxifen in premenopausal breast cancer patients[J]. Clin Cancer Res, 2006, 12(15):4614-4618.
7. 鄧窈窕, 張麗, 蔣明, 等. 乳腺癌患者激素受體、人表皮生長因子受體2表達與免疫組織化學分子亞型分析[J]. 華西醫學, 2012, 27(4):491-494.
8. 劉曉光, 徐光煒. C-erbB-2、P53及nm23基因及產物在乳腺癌預后中的意義[J]. 中國腫瘤臨床, 1994, 21(5):391-395.
9. 韓晶, 王培軍, 湯如勇, 等. HER-2基因在乳腺癌中的表達及其與雌激素受體亞型的關系[J]. 第二軍醫大學學報, 2006, 27(11):1268-1269.
10. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index[J]. Breast Cancer Res, 2009, 11(2):R18.
11. Ariga R, Zarif A, Korasick J, et al. Correlation of her-2/neu gene amplification with other prognostic and predictive factors in female breast carcinoma[J]. Breast J, 2005, 11(4):278-280.
12. 李文華, 孫奇, 覃希, 等. ER、PR、C-erbB-2、HMFG在乳腺癌組織中的表達及臨床意義[J]. 山東醫藥, 2011, 51(47):54-56.
13. 郭麗英, 郭晨明, 馬方婧, 等. 乳腺癌雌激素受體表達和臨床病理因素的關系[J]. 新疆醫科大學學報, 2009, 32(1):48-50.
14. 胡應光. 乳腺癌ER、PR、P53、C-erbB-2表達的臨床意義[J]. 中國基層醫藥, 2007, 14(6):941-942.
15. 姚衛康, 包建英, 吳德明, 等. C-erbB-2、ER、PR在乳腺癌中的表達及其臨床意義[J]. 蘇州大學學報·醫學版, 2007, 27(4):569-571.
16. 闞秀, 沈丹華, 史斌, 等. 關于乳腺普通性增生、不典型增生和原位癌相互關系及鑒別診斷的探討[J]. 中華病理學雜志, 2004, 33(4):14-17.
17. 李金鋒, 鄭德清. 乳腺浸潤癌癌前病變的研究現狀[J]. 國外醫學·腫瘤學分冊, 2002, 29(3):213-216.

West China Medical Journal

Correlation between Expression of Estrogen Receptor and Progesterone Receptor and Clinicopathologic Factors in Patients with Primary Breast Cancer

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content